Article Versions Notes

Smith D, Robledo KP, Yip S, Cummins MM, Kok P-S, Lee YC, Friedlander M, Baron-Hay S, Shannon C, Coward J, et al. Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA). Cancers. 2023; 15(1):254. https://doi.org/10.3390/cancers15010254

Smith, Deborah, Kristy P. Robledo, Sonia Yip, Michelle M. Cummins, Peey-Sei Kok, Yeh Chen Lee, Michael Friedlander, Sally Baron-Hay, Catherine Shannon, Jermaine Coward, and et al. 2023. "Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA)" Cancers 15, no. 1: 254. https://doi.org/10.3390/cancers15010254

Smith, D., Robledo, K. P., Yip, S., Cummins, M. M., Kok, P. -S., Lee, Y. C., Friedlander, M., Baron-Hay, S., Shannon, C., Coward, J., Beale, P., Goss, G., Meniawy, T., Lombard, J., Spurdle, A. B., Andrews, J., Stockler, M. R., Mileshkin, L., & Antill, Y., on behalf of the Australia New Zealand Gynaecological Oncology Group (ANZGOG). (2023). Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA). Cancers, 15(1), 254. https://doi.org/10.3390/cancers15010254